Trial ID 20156 | Maryland Oncology Hematology Trial ID 20156 – Maryland Oncology Hematology

Trial ID 20156

Trial Information - Phase III

A Phase III randomized study to assess the efficacy and safety of alpelisib(BYL719) in combination with olaparib in patients with BRCA wild-type, platinum-resistant or refractory high grade serous ovarian cancer.

Protocol ID: CBYL719K12301

Sponsor: Novartis Pharmaceuticals Corporation

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Ovarian

Investigator

Min MD, Frederick

Status

OPEN TO ENROLLMENT

Sponsor

Novartis Pharmaceuticals Corporation

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology